Volasertib is under clinical development by Notable Labs and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Volasertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Volasertib overview
Volasertib (BI 6727) is under development for the treatment of myelodysplastic syndrome, rhabdomyosarcoma, relapsed/refractory acute myeloid leukemia (AML) and solid tumors including leukemia, lymphoma and pediatric leukemia . The drug candidate is administered as intravenous infusion. The drug targets polo-like kinase 1 (PLK-1). It is a new chemical entity (NCE). It is being developed based on Predictive Precision Medicine Platform.
It was also under development for the treatment of refractory anemia with excess blasts, chronic myelomonocytic leukemia (CMML), metastatic urothelial cancer, acute myeloid leukemia, ovarian cancer, non-small cell lung cancer, acute lymphoblastic leukemia, relapsed and refractory cutaneous T-cell lymphoma, peripheral T-cell lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma and burkitt lymphoma.
Notable Labs overview
Notable Labs, formerly Vascular Biogenics, operates as a provider of biopharmaceutical products. The company discovers, develops and commercializes gene therapy medicines to treat cancer and inflammatory diseases. Its pipeline products include volasertib, which provides NBL-001; fosciclopirox and a a predictive precision medicine platform. Notable Labs uses its proprietary vascular targeting system technology to enable the systemic administration of gene therapy and improve angiogenic blood vessels. The company carries out its business activities through its subsidiaries in Delaware, the US. Notable Labs is headquartered in Foster City, California, the US.
For a complete picture of Volasertib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
